CagriSema, Novo Nordisk’s combination of semaglutide and the amylin analog cagrilintide, just had the best month of its development program. On September 21, 2026, Novo announced that CagriSema produced more weight loss than tirzepatide in a head-to-head Phase 3 trial. Nine days later, it presented brain imaging data showing the compound changed how the brain responds to food. An FDA decision is expected before the end of the year.
The headline is real. The context matters just as much.
The win came in adults with type 2 diabetes over 68 weeks. CagriSema at its lower dose produced 12.4% average weight loss, compared with 9.1% for tirzepatide. Blood sugar control was comparable between the two. For a compound that spent much of 2026 being called a disappointment, that is a meaningful reversal.
Here is the catch. The tirzepatide arm used its lowest dose. In February, a separate head-to-head trial in adults with obesity tested CagriSema at full strength against tirzepatide at its highest dose. Tirzepatide came out ahead, 25.5% to 23.0%, and CagriSema missed its main goal. The scoreboard now depends on which doses are compared and in which population, and neither result settles which compound is stronger overall. For how tirzepatide’s two-receptor design compares with semaglutide alone, see tirzepatide vs semaglutide.
The September 30 data may be the more interesting story for researchers. Presented at the European Association for the Study of Diabetes meeting, a year-long brain imaging study found that CagriSema changed activity in brain regions tied to cravings and reward when participants viewed high-calorie food. Participants also reported fewer cravings and less “food noise,” the constant background thoughts about eating. Separate analyses in adults with type 2 diabetes showed less fat around the liver and pancreas, and early bone markers that held steady despite substantial weight loss. These findings were presented at a meeting and have not yet been published in a peer-reviewed journal.
Why does this matter beyond one product? Because CagriSema is the clearest test yet of amylin as a second pathway. Amylin is a hormone released by the pancreas alongside insulin. It signals fullness through a different route than GLP-1, which is why combining the two is expected to add something rather than repeat it. If approved, CagriSema would be the first amylin-based compound approved for weight management, and every amylin program behind it, from single-molecule designs to pure amylin compounds, will be measured against it. We map that pipeline in next generation GLP-1 peptides.
Tolerability is the other question to watch. Like semaglutide alone, CagriSema’s most common side effects are gastrointestinal and occur mostly during dose escalation. Whether adding amylin changes that profile at scale is something the FDA review will weigh. For how these effects work across the class, see GLP-1 peptides: common side effects observed in research.
Novo submitted CagriSema to the FDA in December 2025 and expects a decision in the fourth quarter of 2026. No public decision date has been announced. For background on the semaglutide half of the combination, see our semaglutide research overview.
To explore how peptides are studied and applied across research settings, visit our Research Library.
CagriSema Reduces Food Noise and Shows Benefits in Organ and Bone Health — Novo Nordisk, 2026